Fortress Biotech, Inc.
No enriched coverage for $FBIOP in the last 7 days.
No SEC Form 4 filings for $FBIOP in the last 30 days.
See all $FBIOP insider activity →Fortress Biotech repaid the remaining $15.0M of its Oaktree senior secured credit facility on Sept 30, 2026, including accrued interest and a prepayment fee, and terminated the agreement. The company's indebtedness was deemed paid in full, and all liens were released.
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “ Company ”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “ Oaktree Agreement ”) with Oaktre
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys
Recent FBIOP coverage spans financial news, corporate actions and earnings.
Fortress Biotech repaid the remaining $15.0M of its Oaktree senior secured credit facility on Sept 30, 2026, including accrued interest and a prepayment fee, and terminated the agreement. The company's indebtedness was deemed paid in full, and all liens were released.
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “ Company ”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “ Oaktree Agreement ”) with Oaktre
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys
Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANG
The article provides a same-session price/volume surge and moving-average context, but no new fundamental catalyst.
AlphAI scores every news story that mentions FBIOP with an AI model for sentiment and relevance, and aggregates insider trades from Fortress Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fortress Biotech repaid the remaining $15.0M of its Oaktree senior secured credit facility on Sept 30, 2026, including accrued interest and a prepayment fee, and terminated the agreement. The company's indebtedness was deemed paid in full, and all liens were released.
1 min readFortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “ Company ”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “ Oaktree Agreement ”) with Oaktre
1 min readFortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys
7 min readFortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANG
2 min readFortress Biotech’s (NASDAQ: FBIOP) shares rose 5.2% on Monday, trading between $20.70 and $20.48 versus a prior close of $19.47, according to market data. Volume was about 105,677 shares, up 345% from the average 23,769. The stock is above its 50-day ($14.56) and 200-day ($11.96) moving averages.
2 min readThis article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this specific stock. The content seems to be a snapshot of a financial data platform's entry for FBIOP, showing it's publicly traded and offers various analytical tools.
2 min readFortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. This PRV was issued following the FDA approval of ZYCUBO for Menkes disease, with Sentynl Therapeutics having assumed responsibility for its development and commercialization. Cyprium is also eligible for royalties and milestones from Sentynl, and will pay 20% of the PRV proceeds to the NIH.
3 min readFortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readTotal net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of ...
4 min readFDA-approved Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release ) is available in the United States for the treatment of inflammatory lesions of rosacea in adults
2 min read
